Tarsus Pharmaceuticals, Inc.

NasdaqGS TARS

Tarsus Pharmaceuticals, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2024: USD -127.80 M

Tarsus Pharmaceuticals, Inc. EBIT is USD -127.80 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -22.25% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Tarsus Pharmaceuticals, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -104.54 M, a -68.52% change year over year.
Tarsus Pharmaceuticals, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -62.04 M, a -558.00% change year over year.
Tarsus Pharmaceuticals, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -9.43 M.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NasdaqGS: TARS

Tarsus Pharmaceuticals, Inc.

CEO	Dr. Bobak R. Azamian M.D.
IPO Date	Oct. 16, 2020
Location	United States
Headquarters	15440 Laguna Canyon Road
Employees	244
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Key trends

Past 5 years